tesaglitazar

Tesaglitazar is a small molecule, dual peroxisome proliferator-activated receptor (PPAR) agonist with activity at both PPARα and PPARγ. It was developed as a potential treatment for type 2 diabetes and metabolic syndrome, aiming to improve insulin resistance and dyslipidemia by modulating glucose and lipid metabolism. Tesaglitazar demonstrated the ability to lower fasting plasma glucose, improve glucose tolerance, reduce insulin levels, decrease triglycerides, and increase HDL cholesterol in clinical studies. Despite reaching phase III clinical trials, its development was discontinued by AstraZeneca in May 2006 due to concerns over its benefit/risk profile—specifically elevations in serum creatinine and associated decreases in glomerular filtration rate that reversed after discontinuation of the drug[2][3][5][7].

Brand names

Galida

Other names

tesaglitazarAZ 242AZ242AZ-242Galida